Literature DB >> 10571338

Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization.

H Tabandeh1, H W Flynn, I U Scott, M L Lewis, P J Rosenfeld, F Rodriguez, A Rodriguez, L J Singerman, J Schiffman.   

Abstract

OBJECTIVE: To evaluate visual outcomes of untreated submacular choroidal neovascularization (CNV) in patients 50 years of age and older with high myopia.
DESIGN: Retrospective observational case series. PARTICIPANTS: Twenty-two eyes in 22 patients were studied. All were 50 years of age and older with myopia of 6.0 diopters (D) or greater or an axial length of 25.5 mm or greater. Patients had untreated CNV documented by clinical examination and fluorescein angiography at two medical centers between 1986 and 1997. INTERVENTION: Demographic and clinical data were abstracted from patients' medical records. MAIN OUTCOME MEASURE: Visual acuity at 1 year after CNV diagnosis.
RESULTS: The study included 22 eyes of 22 patients (mean age, 63.1 years; mean refraction, -11.0 D). Baseline visual acuity (VA) in the study eye was 20/40 or greater in 2 (9%) patients, 20/50 to 20/150 in 9 (41%) patients, and 20/200 or less in 11 (50%) patients. Drusen were present in seven (32%) eyes, and lacquer cracks were noted in ten (45%) eyes. Mean refractive error was -7.0 D for patients with drusen and -12.5 D for patients without drusen. Choroidal neovascularization was less than 0.25 disc diameters (DD) in 11 (50%) eyes, 0.25 to 0.5 DD in 5 (23%) eyes, and greater than 0.5 DD in 6 (27%) eyes. Visual acuity in the study eye 1 year after CNV diagnosis was 20/40 or greater in 3 (14%) patients, 20/50 to 20/150 in 3 (14%) patients, and 20/200 or less in 16 (73%) eyes. The presence of drusen was significantly associated with older age and a lower degree of myopia but was not associated with size of the CNV or visual acuity outcome.
CONCLUSION: When compared to patients younger than 50 years of age with high myopia and CNV reported in previous publications, the patients in the current series generally have poorer visual outcomes.

Entities:  

Mesh:

Year:  1999        PMID: 10571338     DOI: 10.1016/S0161-6420(99)90484-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  25 in total

1.  Visual outcomes for high myopic patients with or without myopic maculopathy: a 10 year follow up study.

Authors:  Y-F Shih; T-C Ho; C K Hsiao; L L-K Lin
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

2.  Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors.

Authors:  Tugrul Altan; Nur Acar; Ziya Kapran; Yaprak B Unver; Sezin Ozdogan
Journal:  Int Ophthalmol       Date:  2012-02-19       Impact factor: 2.031

Review 3.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

4.  Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues.

Authors:  P J Rosenfeld
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

5.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Amy L Wong; David T L Liu; Dennis S C Lam
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

6.  Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV.

Authors:  Sengul Ozdek; Ahmet Hondur; Gokhan Gurelik; Berati Hasanreisoglu
Journal:  Int Ophthalmol       Date:  2006-11-16       Impact factor: 2.031

7.  Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia.

Authors:  Ariko Kojima; Kyoko Ohno-Matsui; Satoshi Teramukai; Yoko Ishihara; Noriaki Shimada; Takeshi Yoshida; Yoshiharu Sugamoto; Takashi Tokoro; Manabu Mochizuki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-21       Impact factor: 3.117

8.  Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.

Authors:  Izumi Yamamoto; Adam H Rogers; Elias Reichel; Paul A Yates; Jay S Duker
Journal:  Br J Ophthalmol       Date:  2006-07-26       Impact factor: 4.638

9.  Surgical removal of subfoveal choroidal neovascularization in pathologic myopia: a 12-year follow-up study.

Authors:  R Hera; C Chiquet; J P Romanet
Journal:  Int Ophthalmol       Date:  2013-03-29       Impact factor: 2.031

10.  Characteristics of patients with a favorable natural course of myopic choroidal neovascularization.

Authors:  Kengo Hayashi; Kyoko Ohno-Matsui; Takeshi Yoshida; Kanako Kobayashi; Ariko Kojima; Noriaki Shimada; Kenjiro Yasuzumi; Soh Futagami; Takashi Tokoro; Manabu Mochizuki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-07-28       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.